跳至主要内容
临床试验/EUCTR2007-003548-32-LT
EUCTR2007-003548-32-LT进行中(未招募)不适用

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency Who Have Inadequate Glycemic Control

Merck & Co., Inc.0 个研究点目标入组 500 人开始时间: 2009年2月19日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • ?Patient has type 2 diabetes mellitus (T2DM).
  • ?Patient has moderate or severe renal insufficiency as indicated by a creatinine clearance <50 mL/min and is not likely to require dialysis throughout the duration of the study.
  • ?Patient is = 30 years of age on day of signing informed consent.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • ?Patient is on dialysis or is likely to need dialysis during the study.
  • ?Patient has type 1 diabetes mellitus or a history of ketoacidosis.
  • ?Patient has been diagnosed with a significant cardiovascular disorder (e.g. MI or unstable angina) or has had a cardiovascular procedure (e.g. CABG or PTCA) within 3 months of signing informed consent.
  • ?Patient has new or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent.

研究者

相似试验

进行中(未招募)
1 期
A Blinded Study to Evaluate Higher Versus Standard Adalimumab Doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal UlceratioMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's disease
EUCTR2013-001746-33-BEAbbVie Deutschland GmbH & Co. KG514
进行中(未招募)
1 期
A Blinded Study to Evaluate Higher Versus Standard Adalimumab doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal UlceratioMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's disease
EUCTR2013-001746-33-ATAbbVie Deutschland GmbH & Co. KG500
已完成
3 期
Efficacy and Safety Study of Alogliptin Compared to Glipizide in Elderly Diabetics
CTRI/2009/091/000123Takeda Global Research &amp; Development Centre (Europe) Ltd (TGRD)61 AldwychLondon WC2B 4AE United Kingdom
进行中(未招募)
1 期
A Blinded Study to Evaluate Higher Versus Standard Adalimumab doses for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Crohn's Disease and Evidence of Mucosal UlceratioCrohn's diseaseMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders
EUCTR2013-001746-33-CZAbbVie Deutschland GmbH & Co. KG600
进行中(未招募)
1 期
A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of MK-0431 Monotherapy in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - MK-0431 Monotherapy Study in Patients with Type 2 DMMedDRA version: 7.0Level: LLTClassification code 10045242Type 2 Diabetes Mellitus
EUCTR2004-000313-19-HUMerck & Co., Inc.18